anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Modern resin hemoadsorption/hemoperfusion for calcium channel blocker overdose is yet to be reported. The characteristics of calcium channel blockers make them unamenable to removal by hemodiafiltration or charcoal hemoperfusion; however, elimination, using styrene bead adsorption in an ex vivo model, has been demonstrated. Its clinical use is described.
CASE REPORT: A man in his 20s was admitted with shock into the Intensive Care Unit (ICU) after an overdose of amlodipine and risperidone. Resuscitation and supportive care were administered, but hypotension did not resolve despite the administration of intravenous fluids, infusions of calcium, adrenaline, and hyperinsulinemic-euglycemic therapy. Methylene blue was then administered to maintain the mean arterial pressures. However, the hemodynamic effect did not allow the weaning of the adrenaline. Drug clearance using hemoadsorption/hemoperfusion was attempted using a styrene resin filter (Jafron HA230; Jafron Biomedical Co., Ltd., Guangdong, China). During the two hemoperfusion sessions (6 h duration each, and 18 h apart) the patient had successfully weaned off all supportive measures, with lactate levels returning to normal and was later discharged home. At the end of each session, significant amlodipine concentrations were detected in blood aspirated from both filters, suggesting enhanced clearance. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Our case illustrates a temporal relationship between resin hemoperfusion therapy, resolution of hemodynamic instability, and shock without proving causation. Significant amlodipine elimination was suggested by high concentrations found in blood from the filter. At the same time, shock resolution after initiation of hemoperfusion occurred in less than one elimination half-life of amlodipine.
Adult Patients

The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. Discontinue pantoprazole sodium for injection as soon as the patient is able to tolerate oral treatment. Switch to an appropriate oral medication within 10 days of starting pantoprazole sodium for injection.

  


Pediatric use information is approved for PROTONIX® I.V. (pantoprazole sodium) for injection. However, due to Wyeth Pharmaceuticals LLC marketing exclusivity rights, this drug product is not labeled with that information.
The invention relates to medicine for preventing epidemic influenza. The medicine for preventing the epidemic influenza has an obvious effect mainly aiming at painful early-stage shock. The medicine for preventing the epidemic influenza is processed according to modern scientific research and through reasonable screen according to a dosage method of assistant and guide of crude drugs. The medicine for preventing the epidemic influenza accords with scientific laws and is good in taste. Folium isatidis, radix isatidis and lophantherum gracile are ground into powder to be mixed so as to form the medicine for preventing the epidemic influenza. The purpose of the medicine for preventing the epidemic influenza is to improve blood perfusion of systemic tissue, recover and maintain homergy and organ functions of a patient, and not simply improve blood pressure. The medicine for preventing the epidemic influenza is simple and remarkable in effect.
PURPOSE: It is unclear if postoperative pain experience and opioid consumption differ in patients undergoing primary vs repeat Cesarean delivery (CD) as prior studies have yielded conflicting results and none used the same patients as their own controls. We sought to compare opioid consumption and pain scores in patients undergoing both a primary and a first repeat CD, using the same patients as their own controls.
METHODS: We conducted a single-centre historical cohort study of patients who underwent both a primary and a first repeat CD under neuraxial anesthesia between 1 January 2016 and 30 November 2022. The same standardized multimodal analgesic regimen was used for all patients. The primary outcome was opioid consumption in oral morphine equivalents (OME) at 48 hr after surgery. Secondary outcomes included area under the curve for pain scores at 24 and 48 hr, and opioid consumption at 24 hr.
RESULTS: We included 409 patients. In unadjusted analysis, there were no significant differences between primary and repeat CD in median [interquartile range] opioid consumption at 48 hr (45 [15-89] mg vs 45 [15-83] mg OME) or in any of the secondary outcomes. In the multivariable model adjusting for age, body mass index, anxiety, depression, priority, surgery duration, gestational age, receipt of postoperative ketorolac, and neuraxial type, repeat CD was still not associated with increased opioid consumption compared with primary CD (adjusted rate ratio, 1.20; 95% confidence interval, 0.95 to 1.51).
CONCLUSION: In this retrospective study, we found no differences in postoperative opioid consumption or reported pain scores in patients who underwent both a primary and a first repeat CD.
BACKGROUND: Posterior interosseous neuropathy is an uncommon cause of peripheral dystonia.
CASE REPORT: A 62-year-old man awakened and noticed right finger drop. A neurological examination revealed posterior interosseous neuropathy with dystonia-like finger movements. Abnormal movements were predominantly observed in the right thumb, ring finger, and little finger. Within 2 weeks, the muscle weakness in the right fingers had completely improved. However, a brief abnormal posture of the right thumb was persistent.
DISCUSSION: The residual abnormal posture of the right thumb may reflect pre-existing motor control abnormalities, which may have contributed to the onset of posterior interosseous neuropathy-associated peripheral dystonia.
OBJECTIVE: Osteonecrosis of the femoral head (ONFH) is a disease that occurs frequently in young and middle-aged people. Because of its high disability rate, it affects the ability to work, so the early treatment of this disease is particularly important. This retrospective study aimed to evaluate the clinical efficacy of hip arthroscopy combined with multiple small-diameter fan-shaped low-speed drilling decompression (MSFLD) in treating early-mid stage ONFH (ARCO II-IIIA) compared to MSFLD, with at least 10-year follow-up.
METHODS: A total of 234 patients who underwent hip arthroscopy and MSFLD for ONFH from 1998 to 2012 were analyzed retrospectively. This study enrolled patients between 18 and 60 years old with ARCO stage II-III A, diagnosed clinically and through imaging, in accordance with the 2021 guidelines for the treatment of ONFH. Clinical data, including demographics, operation mode, BMI, pre- and postoperative Harris score, and femoral head survival rate, were collected. Patients were divided into hip arthroscopy + MSFLD and MSFLD groups based on the operation mode. The t-test was used to compare the postoperative efficacy, Harris scores, and survival rates of the femoral head between the two groups.
RESULTS: Among the 234 patients, 160 cases were followed up, including 92 cases in the hip arthroscopy + MSFLD group and 68 cases in MSFLD group, the follow-up rate was 68.38%, and the follow-up time was (10-22)14.11 ± 3.06 years. The Harris score (80.65 ± 6.29) in the hip arthroscopy + MSFLD group was significantly higher than that in the MSFLD group (p = 0.00), and the survival rate of femoral head (5-year survival rate was 84.78%, 10-year survival rate was 23.91%) was also higher than that in the MSFLD group (5-year survival rate was 63.24%, 10-year survival rate was 8.82%). The 5-year and 10-year survival rates of patients with ARCO II were 82.11% and 28.42%, which were better than 54% and 33% for ARCO III A. The femur head survival rate of alcoholic ONFH (5-year survival rate 61.54%, 10-year survival rate 9.23%) was significantly higher than that of other types of ONFH.
CONCLUSION: Clinical follow-up of at least 10 years suggests that hip arthroscopy combined with MSFLD is an effective treatment for early-mid stage ONFH, with good clinical effect and high survival rate of femoral head.
BACKGROUND: Colorectal cancer (CRC) is one of the leading causes of death globally. Multiple factors may contribute to the pathogenesis of CRC, including the abnormalities in the functioning of the endogenous opioid system (EOS) or adiponectin-related signaling. The aim of our study was to evaluate if differences in the expression of opioid receptors (ORs) influence the development of CRC and if modulation of adiponectin receptors using AdipoRon, a selective AdipoR1 receptor agonist, affects colorectal carcinogenesis.
METHODS: Naltrexone, an opioid receptor antagonist, was injected intraperitoneally every second day for 2 weeks, at the dose of 1 mg/kg in healthy Balb/C mice to induce changes in ORs expression. CRC was induced by a single intraperitoneal injection of azoxymethane (AOM) and the addition of dextran sodium sulfate (DSS) into drinking water in three-week cycles. The development of CRC was assessed using macro- and microscopic scoring and molecular analysis (RT qPCR, ELISA) after 14 weeks.
RESULTS: Naltrexone significantly increased the mRNA expression of Oprm1, Oprd1, and Oprk1 in the mouse colon and in the brain (non-significantly). The pretreatment of mice with naltrexone aggravated the course of CRC (as indicated by tumor area, colon thickness, and spleen weight). The level of circulatory adiponectin was lowered in mice with CRC and increased in the colon as compared with healthy mice. The β-endorphin level was increased in the plasma of mice with CRC and decreased in the colon as compared to healthy mice. AdipoRon, AdipoR1 agonist, worsened the CRC development, and pretreatment with naltrexone enhanced this negative effect in mice. CRC did not affect the expression of the Adipor1 gene, but the Adipor1 level was increased in mice pretreated with naltrexone (AOM/DSS and healthy mice). AdipoRon did not influence the expression of opioid receptors at the mRNA level in the colon of mice with CRC. The mRNA expression of Ptgs2, Il6, Nos2, Il1b, Il18, Gsdmd, and Rela was increased in mice with CRC as compared to the healthy colon. AdipoRon significantly decreased mRNA expression of Ptgs2, Il6, Il1b, and Il18 as compared to CRC mice.
CONCLUSION: EOS and adiponectin-related signaling may play a role in the pathogenesis of CRC and these systems may present some additivity during carcinogenesis.
Arm 1: Dry needling group. Dry needling will be done with painful trigger point and it will be waited for about 20 minutes. This treatment will be repeated once a week for 3 weeks.No medication is used in this treatment.
Patients presenting to the ED with a primary complaint of shortness of breath will a have blood sample collected at enrollment and tested using the Triage® Profiler S.O.B. Panel (measuring creatine kinase MB \[CK-MB\], myoglobin, troponin I, B-type natriuretic peptide \[BNP\], D-dimer). The test is used as an aid in the diagnosis of myocardial infarction (MI), an aid in the diagnosis and assessment of severity of heart failure (HF), and an aid in the assessment and evaluation of disseminated intravascular coagulation including pulmonary embolism (PE). Phase I is an observational study and results of the Triage Profiler S.O.B. panel will be blinded to all attending physicians and health care workers. In Phase II, patients will be assigned to either the experimental arm or the control arm of the study. In the experimental arm, the Triage Profiler S.O.B. Panel results will be available to the treating physician and can be incorporated into the decision making process. In the control arm, treating physicians and staff will be blinded to the Triage Profiler S.O.B. Panel results. Time to appropriate treatment, length of ED stay, patient outcome and hospital costs will be assessed in all patients and used to determine the impact of Triage Profiler S.O.B Panel on these parameters. Furthermore, the diagnostic accuracy of the Triage Profiler S.O.B Panel will be calculated.
The invention relates to a new South China Sea conus M-superfamily toxin gene Lt3.2 and a polypeptide sequence lt3b coded by the same, and the application of the polypeptide in preparing tool medicine for the neurobiological research and analgesic drugs. By constructing cDNA library, the new M-superfamily toxin gene is obtained by cloning the South China Sea conotoxin, the cDNA sequence of Lt3.2 is shown by Sq. (400) 1 in the sequences table. As for the polypeptide (conotoxin lt3b) coded by the gene, the amino acid sequence of the precursor peptide is shown in Sq. (400) 2 of the sequences table, and the amino sequence of the presumed mature peptide is shown in Sq. (400) 3 of the sequences table. The neurotoxin lt3b of the invention can increase the opening current of the sodium channel and has an effect of abirritation. The neurotoxin lt3b can also be used for preparing tool medicine for the neurobiological research and analgesic agent.
Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
Oral squamous cell carcinoma (OSCC) is a common malignant tumor. Importin7 (IPO7) is responsible for nucleoplasmic transport of RNAs and proteins, and it has been confirmed to be involved in the development of human cancers. This study aimed to explore the function and mechanism of IPO7 in OSCC. IPO7 expression in tissues and cells was determined by RT-qPCR. Cell proliferative, migratory, and invasive capabilities were detected through transwell assay and colony formation assay. Mice xenograft models were established for evaluating tumor growth. Autophagy was estimated by the LC3 levels in cells through western blot and immunofluorescence (IF). Western blot was utilized to detect the key proteins in PERK/EIF2AK3/ATF4 pathway for assessing the endoplasmic reticulum stress (ERS). The interaction of IPO7 and homeobox A10 (HOXA10) was tested by GST pull-down assay and Co-IP assay. ChIP assay and luciferase reporter assay were utilized to determine the combination of HOXA10 and EIF2AK3. We proved that IPO7 was upregulated in OSCC tissues and cells, and its depletion reduced cell proliferation, migration, invasion and tumor growth. Furthermore, LC3 expression in cells was found to be reduced by IPO7 knockdown. IPO7 promoted OSCC tumor metastasis by activating autophagy. Additionally, we discovered that IPO7 could regulate ERS by activating the PERK/ATF4 pathway. EIF2AK3 upregulation can promote cell autophagy. Furthermore, IPO7 was proven to promote nuclear translocation of HOXA10 in cells. EIF2AK3 promoter can bind to HOXA10. Rescue assay confirmed that HOXA10 upregulation can reverse the effect of IPO7 silencing on OSCC progression. IPO7 can enhance proliferation, migration, invasion, and autophagy by nuclear translocation of HOXA10 and the activation of EIF2AK3/ATF4 pathway in OSCC.
The present invention relates to a process of entrapping genetic materials in nanoparticles of inorganic metal salts of size below 100 nm diameter to form non-viral carriers for delivery of genes. The process comprises the steps of dissolving surfactants and a cosurfactant in oil to obtain reverse micelles. An aqueous solution of genetic material is added to the reverse micelles. Thereafter the reverse micelles are divided into two equal parts. To one part, aqueous solution of inorganic metal salts is dissolved to obtain optically clear and transparent reverse micelles. To the second part aqueous solution of precipitating agent is added to obtain optically clear and transparent reverse micelles. The two equally divided parts of reverse micelles are mixed to form inorganic nanopartcles encapsulating added genetic material. Thereafter, the nanoparticles are separated from reverse micelles, the inorganic nanoparticles are dispersed in water and dialyzed to remove free metal salts, surfactant and oil.
The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a blood plasma sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad disposed along a length of the base and is configured to hold the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The conjugate pad is further configured to receive the blood plasma sample. The test strip also includes a plurality of second and third antibodies that bind to ST2, and the conjugate-ST2 complexes, respectively. The plurality of second antibodies are bound to a membrane in a test location and the plurality of third antibodies are bound to the membrane in a control location.
Biportal endoscopic spinal surgery has become increasingly popular, and indications have expanded. Among these, biportal endoscopic transforaminal lumbar interbody fusion (BE-TLIF) has yielded good results. Herein, we compared the clinical and radiological outcomes of 155 patients treated with BE-TLIF and open posterior lumbar interbody fusion (PLIF) for single-level lumbar degenerative diseases. Clinical outcomes included the visual analog scale for the back (VAS-back) and leg (VAS-leg), Oswestry Disability Index, and EuroQol 5-Dimensions. Radiological parameters and fusion rates were evaluated, and postoperative complications were recorded. In this cohort 68 and 87 patients were treated with BE-TLIF and PLIF, respectively. Both groups showed significant improvements in all clinical parameters compared with baseline, but BE-TLIF exhibited a more significant improvement in VAS-back at 1 and 6 months postoperatively. There were no significant differences in the radiological parameters or fusion rates. BE-TLIF had a significantly longer operation time, whereas PLIF exhibited a significantly higher estimated blood loss and surgical drainage, but no significant differences in postoperative complications. Compared to PLIF, BE-TLIF showed similarly good clinical and radiologic outcomes, with better results in terms of early postoperative outcomes. Thus, BE-TLIF is a viable alternative to PLIF with less back pain at 1 and 6 months postoperatively.
PURPOSE:To obtain the title composition improved in flexibility, etc., by mixing a glycolic acid/lactic acid copolymer of a specified composition as the main component with a low-molecular substance such as a glycolic acid oligomer or a lactic acid oligomer in a specified mixing ratio. CONSTITUTION:A hydrolyzable resin composition is produced by mixing 100 pts.wt. glycolic acid/lactic acid copolymer (A) comprising 20-80mol% repeating glycol units and 80-20mol% repeating lactic acid units with 8-20 pts.wt. at least one low-molecular substance (B) selected from among a glycolic acid oligomer (of a degree of polymerization of 1-30), a lactic acid oligomer (of a degree of polymerization of 1-30), a glycolic acid/lactic acid cooligomer (of a degree of polymerization of 2-30), a glycolide and lactide. The obtained resin composition has a tensile tangent modulus of 1-100kgf/mm<2> and a good flexibility. This resin composition is desirable as a medical material such as a biological insulation material and a substrate for sustainedly releasing a drug and can be hydrolyzed and absorbed by the living body after functioning in the living body for a given time.
A pharmaceutical composition comprising a microbubble/microdroplet cluster composition for use in a method of treatment of diseases, disorders, or injuries of the central nervous system (CNS) is provided. The use comprises acoustic cluster therapy (ACT) wherein a first ultrasound insonation is performed either non-invasively towards the CNS, invasively towards the CNS or towards the heart or a spinal or carotid artery outside the CNS. The cluster composition is pre-, and/or co- and/or post-administered with at least one therapeutic agent. The first insonation at a first frequency and first mechanical index is performed to activate a phase shift of a diffusible component of the microdroplet into the microbubble to form a larger bubble. A second insonation at a second frequency and second mechanical index is performed to facilitate extravasation of the therapeutic agent at the region of interest in the CNS. The second insonation is performed either non-invasively or invasively towards the CNS. The disease or disorder of the CNS may be CNS cancer, brain stroke, Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, or amyotrophic lateral sclerosis.
PCT No. PCT/JP95/00822 Sec. 371 Date Dec. 11, 1996 Sec. 102(e) Date Dec. 11, 1996 PCT Filed Apr. 25, 1995 PCT Pub. No. WO95/29694 PCT Pub. Date Nov. 9, 1995The present invention relates to an agent accelerating collagen decomposition and a therapeutic agent for fibrosis disorder containing HGFs (Hepatocyte Growth Factors) as an active ingredient. The active ingredients HGFs accelerate the decomposition of collagen (increase of collagenase activity), and can effectively treat fibrosis disorder by the acceleration of collagen decomposition. Therefore, according to the present invention, the prevention and treatment of a disease due to reduced collagenase activity and fibrosis disorders characterized by excessive production of fibroblast-derived connective tissue matrix are possible.
Cold is acute upper respiratory inflammation caused by viruses, and occurs during climate changes. Influenza, known as flu, is quite epidemic, has urgent onset, and causes symptoms of ardent fever, sensation of chill, headache, nasal obstruction, a lot of nasal discharge, red, swollen and aching throat, or nausea and vomit, or violent cough. The medicament provided by the invention employs Chinese herbal medicines as raw materials, which are decocted through a traditional method to obtain an oral liquid. The medicament provided by the invention suits the remedy to the case according to nosogenesis, has no toxic or side effect and is suitable for treatment of ardent fever, sensation of chill, headache, nasal obstruction, nasal discharge, red, swollen and aching throat, nausea, vomit and cough. The proved recipe with unique effect for influenza is repeatedly researched for many years, cures many patients in several decades, and has total effective rate of 96% and cure rate of 92% through clinic observation on curative effect. The proved recipe for influenza has strong effect on resisting cold and obvious curative effect on prevention of influenza, can enhance antibiosis and antiviral performance of human body and improve immunization function and has the advantages of short treatment course, fast effectiveness and good stability.
Part 1 will evaluate the pharmacokinetics of single doses of 4 test formulations of LEO 32731 compared with a reference formulation. Part 2 will evaluate the effect of food on the pharmacokinetics of selected test formulations of LEO 32731. Part 3 will evaluate the tolerability and safety of selected test formulations of LEO 32731 after multiple dosing.

Based on data from Part 1, up to 3 formulations will be taken forward to Part 2. If none of the formulations are considered appropriate to take forward to Part 2, the trial will stop after Part 1. Similarly, based on data from Part 2, up to 2 formulations will be taken forward to Part 3. If none of the formulations are considered appropriate to take forward to Part 3, the trial will stop after Part 2.
The P3 mobile intervention in its current form sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.